ArticleJournal of molecular histology2026
Inhibition of RBM25 preserves cardiac mitochondrial homeostasis and attenuates ischemic heart failure.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heart failure (HF) after myocardial infarction (MI) is a serious complication that endangers the health of the patient. Mitochondrial dysfunction is an important mechanism in the development of ischemic HF. RNA-binding motif protein 25 (RBM25) is an RNA-binding protein that regulates a variety of biological processes and has been associated with HF. However, its role and underlying mechanism in mitochondrial dysfunction in ischemic HF remain unclear. Left anterior descending artery was ligated to establish an MI model in male C57BL/6 N mice, and cardiac function was evaluated by echocardiography and BNP levels at 4 weeks after ischemia. RBM25-overexpressing AC16 cell lines were constructed using a CRISPR-Cas9-mediated genome editing system. Adeno-associated virus 9-RBM25 shRNA was used to knock down RBM25 in mice. Mitochondrial morphology was observed by transmission electron microscopy, and protein expression was quantified by Western blotting. Cardiac pathology was evaluated by hematoxylin & eosin and Masson staining. Induction of post-ischemic HF in the MI model led to elevated RBM25 protein expression and impaired mitochondrial function in cardiomyocytes. Furthermore, overexpression of RBM25 in AC16 cells altered the expression of mitochondria-associated proteins. Notably, in vivo experiments showed that the knockdown of RBM25 could improve cardiac function after ischemia, along with maintaining mitochondrial morphology and the expression of mitochondrial-related proteins. These findings suggest that RBM25 could mediate HF progression post-infarction by impairing mitochondrial function. Thus, inhibition of RBM25 may have therapeutic potential in slowing down the progression of HF.
Indexed as
Identifiers
42611364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.